DUBLIN–(BUSINESS WIRE)–The “Global Markets for Research Antibodies” report has been added to ResearchAndMarkets.com’s offering.
The global market for research antibodies was valued at approximately $3.5 billion in 2022. Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022. The primary antibody segment recorded $2.4 billion in revenue in 2022, and this segment is expected to grow at a CAGR of 9.7% during the forecast period.
The high growth rate of this segment is attributed to such factors as demand of antibodies research, the COVID- 19 pandemic, other infectious diseases and an increase in R&D activities by key companies to emerge with new antibodies to counter the global rise in different infectious diseases (e.g., HIV, malaria, dengue). The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies. Antibodies for each of its many forms of post-translational modifications are needed, even for the same protein molecule. This is likely to propel the growth of the market for research antibodies during the forecast period.
Primary antibodies are used alone or in combination with a secondary antibody. Primary antibodies conjugated to fluorochromes are used in flow cytometry, whereas in microscopy, a primary-secondary antibody combination is used to increase the signal.
The secondary antibody segment is expected to grow at a CAGR of 7.8% during the forecast period. A rise in basic or clinical research to detect specific cell or tissue components (antigens), a shorter assay time, an increase in the versatility, antigen signal detection and amplification are likely to fuel the segment’s growth in the next few years.
This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.
The Report Includes
- An overview of the global market landscape related to the research antibodies
- In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
- Evaluation of the current market size and revenue growth prospects specific to research antibodies, accompanied by a comprehensive market share analysis categorized by product, clonality, application, major reactivities, host species, end-user, and geographical region
- Discussion on the factors affecting the companies’ market shares, the current strategies of antibody companies, the effect of research funding, and the third-party quality evaluation systems of research antibodies
- Description of antibody technologies, emerging antibody generation technologies and identification of market drivers, restraints and other forces impacting the global market
- Discussion on technological trends in antibody production and application, and information on antibody-based drug discovery and development process
- Impact analysis of COVID-19 on entire pharma industry and discussion on how COVID-19 is related to pharmaceutical industry’s growth slow-down and results in delayed approvals for non-COVID-19-related pharmaceutical/biotech products
- Coverage of new discoveries in biological sciences, rapid technological developments in the IVD industry, new antibody technologies and antibody types, and assessment of antibody-based drug discovery and development
- Discussion on advantages and disadvantages of antibody discovery technologies with examples of antibody production, and information on REpAb technology
- Coverage of FDA and international regulations, details of recent regulatory reforms and list of antibody therapeutics granted in 2018 and insights into government initiatives and funding in emerging markets
- Examination of environmental, social, and corporate governance (ESG) developments, a relevant patent analysis; and merger and acquisitions (M&A), venture fundings, and emerging technologies in the global research antibodies
- Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses, including Abcam Plc, Thermo Fisher Scientific Inc., Cell Signaling Technology Inc., Merck KGaA, Sino Biological Inc., and Bio-Rad
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 485 |
| Forecast Period | 2023 – 2028 |
| Estimated Market Value (USD) in 2023 | $3.7 Billion |
| Forecasted Market Value (USD) by 2028 | $5.8 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global
|
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Chapter 4 Research Antibodies
Chapter 5 Market Dynamics
-
Market Drivers
- New Discoveries in Biological Sciences
- Rapid Technological Developments in the In Vitro Diagnostic Industry
- New Antibody Technologies and Types
- Antibody-Based Drug Discovery and Development
- Developed and Increasing Research Areas
- Increased Government Funding in Emerging Markets
- Need for Further Human Genomic and Proteomic Research
- Need for Quality Antibodies in the Current Research Community
- Need for Antibody Custom Services
- New Application-Focused Technology Platforms
-
Market Restraints
- Limited Research Funding
- Low Validation Technologies
- Decline in Suppliers
- Decrease in Market Acceptance or Brand Trust
- Market and Economic Risk
-
Market Opportunities
- Market Expansion into Emerging Countries
- Development of Novel Research Antibodies
Chapter 6 Market Breakdown by Type of Antibody
Chapter 7 Market Breakdown by Clonality
Chapter 8 Market Breakdown by Major Reactivity
Chapter 9 Market Breakdown by Application
Chapter 10 Market Breakdown by Host Species
Chapter 11 Market Breakdown by End User
Chapter 12 Market Breakdown by Region
Chapter 13 Sustainability in the Research Antibodies Industry: An Environment, Social and Governance Sustainability in the Research
Chapter 14 Emerging Technology for Antibody Discovery and Generation
- Traditional Antibody Discovery and Generation Technologies
- Animal Plasma Isolation
- Hybridoma Generation
- B Cell Screening
- Display Technologies
- Emerging Antibody Discovery and Generation Technologies
- Emerging Trends in the Antibody Production Technologies
- Polyclonal Antibody Sequencing
- Single B Cell Sequencing
- Machine Learning-Assisted Discovery and Generation
- Advantages and Disadvantages of Antibody Discovery Technol0gies
- Examples of Antibody Production and Technologies
- REpAb Technology
- Boehringer Ingelheim’s Partnership with Company
- COVID-19 Vaccines by EABR Technology
- First Therapeutic Antibody
- Challenges and Future Research Direction
Chapter 15 Approved Monoclonal Antibodies, 2018-2023
Chapter 16 M&A and Venture Funding Outlook
Chapter 17 Competitive Landscape
Chapter 18 Company Profiles
- Abcam
- Absolute Antibody
- Agilent Technologies
- Bd Biosciences
- Bio-Rad
- Bio-Techne
- Cell Signaling Technology
- Danaher
- Jackson Immunoresearch Laboratories
- Lonza
- Merck
- Rockland Immunochemicals
- Santa Cruz Biotechnology
- Sino Biological
- Thermo Fisher Scientific
- United States Biological
For more information about this report visit https://www.researchandmarkets.com/r/3sabu6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900